HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Catalase levels in patients with aniridia and/or Wilms' tumor: utility and limitations.

Abstract
The gene for red blood cell (RBC) catalase has recently been mapped to 11p13, and a gene dosage effect has been demonstrated for individuals with triplication or deletion of that region. Deletion of the 11p13 band has also been associated with aniridia, with and without Wilm's tumor. We studied the RBC catalase levels in individuals without detectable chromosomal abnormalities but with aniridia, Wilm's tumor, and the combination of aniridia and Wilms' tumor, to determine whether catalase levels might provide evidence for a submicroscopic chromosomal deletion in the 11p13 region. All karyotypically normal patients were found to have normal catalase levels.
AuthorsR E Ferrell, V M Riccardi
JournalCytogenetics and cell genetics (Cytogenet Cell Genet) Vol. 31 Issue 2 Pg. 120-3 ( 1981) ISSN: 0301-0171 [Print] Switzerland
PMID6273073 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Catalase
Topics
  • Catalase (blood)
  • Chromosome Deletion
  • Chromosomes, Human, 6-12 and X
  • Erythrocytes (enzymology)
  • Female
  • Genes, Dominant
  • Humans
  • Infant
  • Iris (abnormalities)
  • Karyotyping
  • Male
  • Pedigree
  • Wilms Tumor (enzymology, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: